M
Marco Mielcarek
Researcher at Fred Hutchinson Cancer Research Center
Publications - 130
Citations - 6972
Marco Mielcarek is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 39, co-authored 119 publications receiving 5901 citations. Previous affiliations of Marco Mielcarek include University of Washington Medical Center & University of Washington.
Papers
More filters
Journal ArticleDOI
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
Marco Mielcarek,Paul J. Martin,Wendy M. Leisenring,Mary E.D. Flowers,David G. Maloney,Brenda M. Sandmaier,Michael B. Maris,Rainer Storb +7 more
TL;DR: The results show that nonablative HSCT is associated with a syndrome of acute GVHD occurring after day 100 in many patients, and should be taken into consideration in the design of prospective studies comparing GV HD resulting from the two types of transplantation procedures.
Journal ArticleDOI
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria
Mary E.D. Flowers,Yoshihiro Inamoto,Paul A. Carpenter,Stephanie J. Lee,Hans-Peter Kiem,Effie W. Petersdorf,Shalini E. Pereira,Richard A. Nash,Marco Mielcarek,Matthew L. Fero,Edus H. Warren,Jean E. Sanders,Rainer Storb,Frederick R. Appelbaum,Barry E. Storer,Barry E. Storer,Paul J. Martin +16 more
TL;DR: The results suggest that the mechanisms involved in acute and chronic GVHD are not entirely congruent and that chronicGVHD is not simply the end stage of acute GV HD.
Journal ArticleDOI
Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning
Frédéric Baron,Michael B. Maris,Brenda M. Sandmaier,Barry E. Storer,Mohamed L. Sorror,Razvan Diaconescu,Ann E. Woolfrey,Thomas R. Chauncey,Mary E.D. Flowers,Marco Mielcarek,David G. Maloney,Rainer Storb +11 more
TL;DR: New approaches aimed at reducing the incidence of grade 2 to 4 acute GVHD might improve survival after allogeneic HCT after nonmyeloablative conditioning.
Journal ArticleDOI
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?
Daisuke Araki,Brent L. Wood,Megan Othus,Jerald P. Radich,Anna B. Halpern,Yi Zhou,Marco Mielcarek,Elihu H. Estey,Frederick R. Appelbaum,Roland B. Walter +9 more
TL;DR: The similarities in outcomes between patients in MRD-positive morphologic remission and those with active disease at the time of HCT support the use of treatment algorithms that use MRd- rather than morphology-based disease assessments.
Journal ArticleDOI
Cord-Blood Transplantation in Patients with Minimal Residual Disease
Filippo Milano,Ted Gooley,Brent L. Wood,Ann E. Woolfrey,Mary E.D. Flowers,Kristine Doney,Robert P. Witherspoon,Marco Mielcarek,J. Deeg,Mohamed L. Sorror,Ann Dahlberg,Brenda M. Sandmaier,Rachel B. Salit,Effie W. Petersdorf,Frederick R. Appelbaum,Colleen Delaney +15 more
TL;DR: Outcomes in 582 consecutive patients with acute leukemia or the myelodysplastic syndrome who received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blood donor, an HLA-matched unrelated donor, or an Hla-mismatched unrelated donor were compared.